Bioject Medical Technologies Other Current Assets Calculation
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
Cash
Trade Receivables
Inventory
The assets grouped under other current assets are most commonly:
Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Bioject Medical Technologies (Bioject Medical Technologies) Business Description
Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
| James C Gale |
director |
152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019 |
| Sanders Morris Harris Inc/fa |
10 percent owner, other: See General Remarks |
600 TRAVIS, SUITE 5900, HOUSTON TX 77002 |
| David S Tierney |
director |
C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
| Edward L Flynn |
director, 10 percent owner |
211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921 |
| Life Sciences Opportunities Fund Ii Lp |
10 percent owner |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Lof Partners Llc |
other: See general remarks |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Life Sciences Opportunities Fund Instittutional Ii Lp |
10 percent owner |
152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
| Randal D Chase |
director |
28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7 |
| Brigid Makes |
director |
20245 SW 95TH AVENUE, TUALATIN OR 97062 |
| J Michael Redmond |
officer: Sr. VP Bus Dev. |
10 CANTERBURY ROAD, WINDHAM NH 03087 |
| Elan Corp Plc |
10 percent owner |
TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
| Elan International Services Ltd |
10 percent owner |
C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2 |
| Elan Pharmaceutical Investments Ltd |
10 percent owner |
102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999 |
| John P Gandolfo |
officer: CFO |
62 TERRACE ROAD, WAYNE NJ 07470 |
| Grace K Fey |
director |
1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BJCT has been successfully added to your 